A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree Master of Medicine in Paediatrics (MMed) Johannesburg 2013 / Introduction Invasive pneumococcal disease, including meningitis, caused by Streptococcus pneumoniae is a major cause of morbidity and mortality world-wide. The introduction of pneumococcal polysaccharide-protein conjugate vaccine (PCV) in the United States has resulted in a reduction in incidence of pneumococcal meningitis. PCV was introduced into the South African expanded programme on immunization (EPI) in 2009. Objective We evaluated the temporal association which the introduction of PCV into the South African EPI had on the incidence of pneumococcal meningitis in children. Methods The study was undertaken in Soweto. All children admitted to Chris Hani Baragwanath Academic Hospital (CHBAH) <14 years of age with meningitis from January 2006 to November 2011 were identified through an electronic database and their microbiological records reviewed to identify the causative bacteria. The results were time framed into two groups: prior to introduction of PCV 1 January 2006 to 31 March 2009 (pre-vaccine era) and post PCV-introduction 1 April 2009 to 30 November 2011 (post-vaccine era). Results 783 patients were admitted with suspected meningitis during the study period, of these 243 (31.0%) met the criteria for bacterial meningitis. The incidence of pneumococcal meningitis was decreasing in the CHBAH in-patient paediatric population by 4.7% per annum prior to the introduction of the vaccine in April 2009. The decline in incidence after PCV introduction accelerated to 18% per annum post-vaccine introduction (P=0.391). In the population most at risk for pneumococcal meningitis, children <1 year of age, the annual reduction in incidence of pneumococcal meningitis accelerated from 1.1% in the pre-vaccine era to 43.4% following PCV introduction (P= 0.011). Conclusions The introduction of PCV resulted in a decline in the incidence of pneumococcal meningitis in all age groups. This decline was most dramatic in the <1 year age group.

A Research report submitted to the Faculty of Health Sciences, University of Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of Master of Medicine in Paediatrics Johannesburg 2015 / Children hospitalized with culture-confirmed pulmonary tuberculosis (PTB) frequently present with acute symptoms, possibly because underlying PTB may predispose to superimposed bacterial pneumonia. Immunization of children with pneumococcal conjugate vaccine (PCV) could protect against such superimposed bacterial pneumonia and reduce the incidence of PTB hospitalization. OBJECTIVE We studied the temporal association of childhood immunization with pneumococcal conjugate vaccine on the incidence of hospitalization for culture-confirmed PTB in children. METHODS A retrospective study on the incidence of hospitalization for culture-confirmed childhood PTB at Chris Hani Baragwanath Academic Hospital was undertaken from 2005 to 2012. This included a pre-PCV era (2005-2008) and a PCV era (2011-2012). RESULTS Overall, there was a 69.2% (95% CI: 62.8-74.6%) decline in the incidence of hospitalization for culture-confirmed PTB when comparing the PCV and pre-PCV-eras, with the decline in HIV-uninfected children only significant in the 3-11 month age category and the decline in HIV-infected significant across all age categories. There was a trend for reduced pneumococcal bacteraemia in the PCV era compared to the pre-PCV era, with the odds of having a blood culture positive for pneumococcus being 1.91-fold (95% CI, 0.26-84.56) greater in the Pre-PCV era. CONCLUSION There has been a significant decline in culture-confirmed PTB hospitalization in children comparing the pre-PCV to the PCV-era. However, the incidence of culture-confirmed PTB prior to the introduction of PCV had been reduced to low levels due to antiretroviral therapy. This confounder together with the retrospective ecological study design and other several possible confounders limited any robust estimate as to whether there was a temporal association between PCV immunization and incidence of culture-confirmed PTB hospitalization in our study setting.

Source: Masters Abstracts International, Volume: 47-06, page: 3554. Adviser: David W. Smith. Includes bibliographical references.

Thesis (M.S.)--University of South Florida, 2007. / Title from PDF of title page. Document formatted into pages; contains 36 pages. Includes bibliographical references.

emezones@gmail.com / Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 yearsold. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule. / This study was funded by Instituto Nacional de Salud, Lima, Peru / Revisión pór pares

Streptococcus pneumoniae is typically an asymptomatic colonizer of the upper respiratory tract but can cause invasive disease in susceptible populations. Pneumococcal vaccines which are currently in use have failed to significantly reduce colonization by S. pneumoniae. To control invasive pneumococcal disease, novel strategies must be utilized. One such strategy is to reduce or eradicate colonization by pneumococcus. Supplementary vaccination with pneumococcal proteins important for colonization could serve to prime the immune system against these targets. This study serves as an initial step towards identification of crucial pneumococcal colonization proteins which may previously have been uncharacterized. Assessing the immune reactivity of human serum to isolated pneumococcal membrane proteins allowed for selection of proteins for analysis via mass spectrometry. Results of MS produced several potential protein targets for further research. Identification of these key surface proteins will pave the way for the creation of a more robust supplementary vaccine, and an improved understanding of the role of non-immunogenic pneumococcal surface proteins.

As infecções pneumocócicas são uma importante causa de morbi-mortalidade entre as crianças. Até 2000, era disponível apenas a vacina pneumocócica polissacarídica 23valente, de uso a partir dos 2 anos de idade. Essa vacina era recomendada para crianças com fibrose cística (FC) e para as asmáticas em uso de corticóide oral, dentre outras recomendações. A partir de 2000, licenciou-se a vacina pneumocócica conjugada 7valente, com grande impacto contra infecções causadas pelos sorotipos vacinais. Nos países onde as crianças não são universalmente vacinadas com essa vacina, as recomendações permanecem as mesmas. Atualmente, os adultos asmáticos estão incluídos nas recomendações para vacinação pneumocócica nos EUA. Há poucos estudos sobre o risco de doença pneumocócica em crianças asmáticas per si e naquelas com fibrose cística e sobre a resposta à vacina pneumocócica conjugada. Salienta-se que ainda não há um critério estabelecido para avaliar a resposta sorológica a essa vacina. Recentemente, foi sugerido o critério de 0,35mcg/ml por Elisa para se correlacionar com proteção para doença invasiva pneumocócica. Objetivou-se determinar a concentração dos anticorpos contra os sorotipos vacinais contidos na vacina pneumocócica conjugada 7valente em crianças com asma moderada em uso de corticóide inalatório e em crianças com fibrose cística; avaliando-as pelos critérios de 0,35mcg/ml, 1,3mcg/ml e aumento de 4 vezes o título pós em relação ao pré-vacinal, para cada sorotipo e para a vacina, considerando-se a positividade para 5 sorotipos. Foram avaliadas 18 crianças em cada grupo. A mediana da idade foi de 82,5m nas asmáticas e 69,5m naquelas com FC. Foi colhida amostra para sorologia pré-vacinação e outra após 2 doses da vacina conjugada. As concentrações de anticorpos para os sorotipos vacinais foram quantificadas pelo Elisa. Para 0,35mcg/ml de corte, a grande maioria nos dois grupos já era positiva à inclusão para os sorotipos vacinais e à vacina. Considerando-se o valor de 1,3mcg/ml, entre os que eram negativos, as crianças asmáticas responderam entre 66,7% (9V) e 100% (14), e as com FC, entre 50% (19F) e 100% (6B e 14); e, em relação à resposta vacinal para esse nível, as asmáticas apresentaram 81,8% de resposta, enquanto as com FC, 91,7%. Avaliando-se pelo aumento de 4 vezes o título pós em relação ao pré-vacinal, a melhor resposta aos sorotipos, nos asmáticos, foi de 33,3% (4, 6B, 14 e 18C), e a nos com FC, 61,1% para o 6B; em termos de resposta vacinal, obteve-se 16,7% e 44,4%, para as asmáticas e aquelas com FC, respectivamente. Não houve interferência da vacinação prévia com a vacina pneumocócica polissacarídica. As medianas dos títulos pós em relação aos pré-vacinais, para os sorotipos, nos dois grupos, apresentaram um aumento significante. Apesar de boa parte das crianças apresentarem uma positividade elevada à inclusão, aquelas que eram negativas tenderam a apresentar uma boa resposta à vacina. / Pneumococcal infections are an important morbi-mortality cause among children. Until 2000, it was only available the 23-valent polysaccharide pneumococcal vaccine for children over two years old. This vaccine was recommended for cystic fibrosis (CF) children and to asthmatics children in use of oral corticosteroids, among other recommendations. From 2000, it was licensed the 7-valent conjugated pneumococcal vaccine, with a great impact against the infections caused by the vaccine serotypes. In the countries that dont make a universally use of this vaccine for children, the recommendations remain the same. At the present time, asthmatic adults are included for the pneumococcal vaccine recommendations in the United States. There are few studies about pneumococcal disease risk with cystic fibrosis children and asthmatics, per si, and about the conjugated pneumococcal vaccine response. It points out that there are no a definitive criteria or evaluation established for the serology response for this vaccine. It was suggested, recently, that the level of 0,35mcg/ml, measured by ELISA, is adequate to correlate with the invasive pneumococcal disease protection. The goal of this study was to determine the antibodies concentration of the seven vaccine serotypes from 7-valent conjugated pneumococcal vaccine among children with moderate asthma in use of inhaled corticosteroids and with cystic fibrosis. It was considered the dosage 0,35mcg/ml and 1,3mcg/ml levels and the four-fold increase between pre- and post-immunization concentrations levels, to each serotype and to the vaccine (positivity for five serotypes or more) for positivity. Eighteen children were included in each study group. The age median was 82,5 months for the asthmatics and 69,5 months for the CF children. A blood sample was taken for pre-immunization serology and a second one after the second vaccine dose was given. The antibodies concentrations for the vaccine serotypes were measured by ELISA. Considering the 0,35mcg/ml levels, the majority of children, in both groups, was positive for vaccine serotypes and for the vaccine as well in the beginning. At the 1,3mcg/ml level, among the children with negative serology, asthmatic children responded between 66,7% (9V) and 100% (14), and those with CF, between 50% (19F) and 100% (6B e 14). Related to the vaccine response for this level, the asthmatics had a 81,8% response, while the CF childrens response was 91,7%. Evaluating for the four-fold increase between pre- and post-immunization concentrations, the best response observed for the vaccine serotypes was 33,3% (4, 6B, 14 e 18C) for the asthmatics. In the CF group the best result was 61,1% (6B). In terms of the vaccine response, it was observed that 16,7% and 44,4% were the results for both the asthmatics and CF group, respectively. The polysaccharide vaccine didnt interfere in the results. The medians of the pre- and post-immunization antibodies concentrations for the vaccine serotypes, in both groups, were significantly increased. Despite those children that were already positive for the criteria evaluated, at the first moment of the study, for those children that were negative, the majority had a positive serology towards the vaccination response.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-03-22T18:32:18Z No. of bitstreams: 1 Milena Soares dos Santos Efeito....docx: 5951904 bytes, checksum: d28e49e9a6c37cb463504bb5cf122c6f (MD5) / Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-03-22T18:32:30Z (GMT) No. of bitstreams: 1 Milena Soares dos Santos Efeito....docx: 5951904 bytes, checksum: d28e49e9a6c37cb463504bb5cf122c6f (MD5) / Made available in DSpace on 2016-03-22T18:32:30Z (GMT). No. of bitstreams: 1 Milena Soares dos Santos Efeito....docx: 5951904 bytes, checksum: d28e49e9a6c37cb463504bb5cf122c6f (MD5) Previous issue date: 2015 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Streptococcus pneumoniae é uma bactéria patogênica que afeta crianças e idosos em todo o mundo, sendo responsável por elevada morbidade e mortalidade, especialmente nos países em desenvolvimento onde o acesso às vacinas pneumocócicas conjugadas (PCVs) é limitado. A colonização da nasofaringe precede o desenvolvimento de infecções e as crianças são o principal reservatório deste patógeno na comunidade. As vacinas pneumocócicas conjugadas reduzem a taxa de colonização e de doenças causadas por sorotipos vacinais, entretanto, pouco se sabe sobre seu efeito em eventos na substituição de sorotipos. Os objetivos deste estudo foram determinar o efeito da vacina pneumocócica conjugada 10-valente (PCV10) na colonização nasofaríngea por pneumococos em crianças menores que um ano, saudáveis e que apresentaram doença crônica ou desordem imunológica nos períodos pré- e pós esquema vacinal primário entre maio de 2011 a janeiro de 2014 e determinar a influência desta vacina na distribuição de sorotipos, da susceptibilidade antimicrobiana e do perfil genotípico dos pneumococos. Foram investigadas 168 crianças, sendo 63 do grupo de portadores de doenças clínicas (Grupo I) e 105 do grupo de crianças sadias (Grupo II). O isolamento, a identificação e a avaliação da resistência antimicrobiana do pneumococo foram realizados através de técnicas microbiológicas convencionais. A determinação dos sorotipos capsulares foi realizada através das técnicas de reação de polimerase em cadeia multiplex e reação de Quellung. A taxa de colonização pneumocócica total foi de 24%, sendo 17% (11/63) e 28% (29/105) para os grupos I e II, respectivamente. Convívio com crianças menores que 6 anos no mesmo domicílio mostrou associação com colonização para o grupo I [OR= 8,36 (IC95%= 1,69-44,70); p=0.004 enquanto que renda foi associada a risco para crianças do grupo II [(OR=3,22; IC95%= 1,22-8,64; p=0,01]. Os sorogrupos/tipos identificados com maior frequência foram: 23F (10%), 19F e 15B/15C (7,5%) e cepas não tipáveis (15%), Após a 3 ª dose da vacina houve uma redução de 7% para 5% na taxa de colonização por sorotipos vacinais e um aumento de três vezes na probabilidade de colonização por sorotipos não vacinais (7% para 21%). Identificamos 17% de não susceptibilidade à penicilina. Os sorotipos PCV10 associados com um ST foram os sorotipos 19F (ST177) e 23F (ST338) e os não associados a PCV10 foram os seguintes: 11A/11D (ST62 e ST408), 15A/15F (ST73), 15B/15C (ST766), 23A (ST42) e 23B (ST727). Os resultados demonstram que três doses da PCV10 reduzem ou estabilizam a colonização por sorotipos vacinais, a despeito da colonização pelos sorogrupos/tipos vacinais 6A/6B, 14 e 23F e destaca-se a colonização por sorotipos não vacinais (6C<7C<13<23A<23B<15A/15F<15B/15C<11A/11D) e cepas não tipáveis, independente do grupo de crianças avaliadas. Embora não tenha sido avaliado o efeito da PCV10 após a 4ª dose da vacina neste estudo, ressaltamos a importância da manutenção da dose de reforço no calendário vacinal do programa nacional de imunizações para que a proteção contra os sorotipos oferecida pela vacina seja alcançada. Estudos epidemiológicos devem continuar para monitorar a taxa de colonização de pneumococos circulantes no período pós-vacinal, bem como as taxas de não susceptibilidade aos antimicrobianos que são essenciais para o direcionamento das estratégias de saúde pública no manejo clínico e prevenção das doenças pneumocócicas. / Streptococcus pneumoniae is a pathogenic bacterium that affects children and elderly throughout the world, accounting for high morbidity and mortality, especially in developing countries where acess to pneumococcal conjugate vaccines (PCVs) is limited. Nasopharyngeal colonization precedes the development of infections and children are the main reservoir of this pathogen in the community. The pneumococcal conjugate vaccine has been effective in reducing colonization and disease by vaccine serotypes, however, little is known about its effect on the overall rate of colonization due to serotypes replacement events. The study aims to evaluate the effect of pneumococcal conjugate vaccine on nasopharyngeal carriage in children younger than one years old, healthy, suffering from crhonic diseases or immune disorders during vaccine primary immunization with PCV-10 between may 2011 and jaanuary 2014 and the influence of this vaccine in the distribution of serotypes, antimicrobial susceptibility and genotypic profile of pneumococcus. A total of 168 children were enrolled, 63 with chronic diseases (Group I) and 105 of the group of healthy children (Group II). The isolation, identification and evaluation of antimicrobial resistance of pneumococci were made using conventional microbiological techniques. The determination of capsular serotypes was performed using the multiplex-PCR and/or Quellung reaction. Overal, the pneumococcal colonization rate was 24%, being 17% (11/63) and 28% (29/105) to group I and II, respectively. Living with children aged up to six 6 years in the same household was associated with colonization in group I[OR= 8,36 (CI95%= 1,69-44,70); p=0.004] and income was associated with risk for children in group II [(OR=3,22; IC95%= 1,22-8,64; p=0,01]. The most frequently serotypes identified were: 23F (10%), 15B/15C (7,5%) and nontypeable strains (15%). A total of 28% (11/40) of serotypes identified in both groups are represented in PCV10. After the 3rd dose of vaccine was reduced from 7% to 5% in vaccine serotypes colonization rate and a three-fold increase in the probability of colonization by serotypes not represented in the PCV-10 (7% to 21%). Penicillin nonsusceptibility was identified in 17% of the isolates. PCV10 serotypes associated with a ST serotypes were 19F (ST177) and 23F (ST338) and not associated with PCV10 were 11A/11D (ST62 and ST408), 15A/15F (ST73), 15B/15C (ST766), 23A (ST42) and 23B (ST727). The results demonstrate that three doses of PCV10 stabilizes or reduces colonization by the vaccine serotypes, regardless of colonization by vaccines types 6A/6B, 14 and 23F and highlight the rates of colonization by non vaccine serotypes (6C<7C<13<23A<23B<15A/15F<15B/15C<11A/11D) and nontypeable pneumococcal, independent of the study group. Although this study was not evaluated the effect of PCV10 after the 4th dose of the vaccine, we emphasize the importance of booster dose of maintenance in the immunization schedule of the national immunization program for the protection offered by the vaccine serotypes is achieved. Epidemiological studies should continue to monitor the rate of colonization of pneumococci circulating in the post-vaccine period and antimicrobial non-susceptibility rates that are essential for the targeting of public health strategies in the clinical management and prevention of pneumococcal diseases.

As infecções pneumocócicas são uma importante causa de morbi-mortalidade entre as crianças. Até 2000, era disponível apenas a vacina pneumocócica polissacarídica 23valente, de uso a partir dos 2 anos de idade. Essa vacina era recomendada para crianças com fibrose cística (FC) e para as asmáticas em uso de corticóide oral, dentre outras recomendações. A partir de 2000, licenciou-se a vacina pneumocócica conjugada 7valente, com grande impacto contra infecções causadas pelos sorotipos vacinais. Nos países onde as crianças não são universalmente vacinadas com essa vacina, as recomendações permanecem as mesmas. Atualmente, os adultos asmáticos estão incluídos nas recomendações para vacinação pneumocócica nos EUA. Há poucos estudos sobre o risco de doença pneumocócica em crianças asmáticas per si e naquelas com fibrose cística e sobre a resposta à vacina pneumocócica conjugada. Salienta-se que ainda não há um critério estabelecido para avaliar a resposta sorológica a essa vacina. Recentemente, foi sugerido o critério de 0,35mcg/ml por Elisa para se correlacionar com proteção para doença invasiva pneumocócica. Objetivou-se determinar a concentração dos anticorpos contra os sorotipos vacinais contidos na vacina pneumocócica conjugada 7valente em crianças com asma moderada em uso de corticóide inalatório e em crianças com fibrose cística; avaliando-as pelos critérios de 0,35mcg/ml, 1,3mcg/ml e aumento de 4 vezes o título pós em relação ao pré-vacinal, para cada sorotipo e para a vacina, considerando-se a positividade para 5 sorotipos. Foram avaliadas 18 crianças em cada grupo. A mediana da idade foi de 82,5m nas asmáticas e 69,5m naquelas com FC. Foi colhida amostra para sorologia pré-vacinação e outra após 2 doses da vacina conjugada. As concentrações de anticorpos para os sorotipos vacinais foram quantificadas pelo Elisa. Para 0,35mcg/ml de corte, a grande maioria nos dois grupos já era positiva à inclusão para os sorotipos vacinais e à vacina. Considerando-se o valor de 1,3mcg/ml, entre os que eram negativos, as crianças asmáticas responderam entre 66,7% (9V) e 100% (14), e as com FC, entre 50% (19F) e 100% (6B e 14); e, em relação à resposta vacinal para esse nível, as asmáticas apresentaram 81,8% de resposta, enquanto as com FC, 91,7%. Avaliando-se pelo aumento de 4 vezes o título pós em relação ao pré-vacinal, a melhor resposta aos sorotipos, nos asmáticos, foi de 33,3% (4, 6B, 14 e 18C), e a nos com FC, 61,1% para o 6B; em termos de resposta vacinal, obteve-se 16,7% e 44,4%, para as asmáticas e aquelas com FC, respectivamente. Não houve interferência da vacinação prévia com a vacina pneumocócica polissacarídica. As medianas dos títulos pós em relação aos pré-vacinais, para os sorotipos, nos dois grupos, apresentaram um aumento significante. Apesar de boa parte das crianças apresentarem uma positividade elevada à inclusão, aquelas que eram negativas tenderam a apresentar uma boa resposta à vacina. / Pneumococcal infections are an important morbi-mortality cause among children. Until 2000, it was only available the 23-valent polysaccharide pneumococcal vaccine for children over two years old. This vaccine was recommended for cystic fibrosis (CF) children and to asthmatics children in use of oral corticosteroids, among other recommendations. From 2000, it was licensed the 7-valent conjugated pneumococcal vaccine, with a great impact against the infections caused by the vaccine serotypes. In the countries that dont make a universally use of this vaccine for children, the recommendations remain the same. At the present time, asthmatic adults are included for the pneumococcal vaccine recommendations in the United States. There are few studies about pneumococcal disease risk with cystic fibrosis children and asthmatics, per si, and about the conjugated pneumococcal vaccine response. It points out that there are no a definitive criteria or evaluation established for the serology response for this vaccine. It was suggested, recently, that the level of 0,35mcg/ml, measured by ELISA, is adequate to correlate with the invasive pneumococcal disease protection. The goal of this study was to determine the antibodies concentration of the seven vaccine serotypes from 7-valent conjugated pneumococcal vaccine among children with moderate asthma in use of inhaled corticosteroids and with cystic fibrosis. It was considered the dosage 0,35mcg/ml and 1,3mcg/ml levels and the four-fold increase between pre- and post-immunization concentrations levels, to each serotype and to the vaccine (positivity for five serotypes or more) for positivity. Eighteen children were included in each study group. The age median was 82,5 months for the asthmatics and 69,5 months for the CF children. A blood sample was taken for pre-immunization serology and a second one after the second vaccine dose was given. The antibodies concentrations for the vaccine serotypes were measured by ELISA. Considering the 0,35mcg/ml levels, the majority of children, in both groups, was positive for vaccine serotypes and for the vaccine as well in the beginning. At the 1,3mcg/ml level, among the children with negative serology, asthmatic children responded between 66,7% (9V) and 100% (14), and those with CF, between 50% (19F) and 100% (6B e 14). Related to the vaccine response for this level, the asthmatics had a 81,8% response, while the CF childrens response was 91,7%. Evaluating for the four-fold increase between pre- and post-immunization concentrations, the best response observed for the vaccine serotypes was 33,3% (4, 6B, 14 e 18C) for the asthmatics. In the CF group the best result was 61,1% (6B). In terms of the vaccine response, it was observed that 16,7% and 44,4% were the results for both the asthmatics and CF group, respectively. The polysaccharide vaccine didnt interfere in the results. The medians of the pre- and post-immunization antibodies concentrations for the vaccine serotypes, in both groups, were significantly increased. Despite those children that were already positive for the criteria evaluated, at the first moment of the study, for those children that were negative, the majority had a positive serology towards the vaccination response.

Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2016-08-09T13:25:07Z No. of bitstreams: 2 Dissertação - Tainá Carvalho Guerreiro - 2015.pdf: 1793254 bytes, checksum: b06a919b2f95dde4661fe77445d3668c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-08-09T13:27:31Z (GMT) No. of bitstreams: 2 Dissertação - Tainá Carvalho Guerreiro - 2015.pdf: 1793254 bytes, checksum: b06a919b2f95dde4661fe77445d3668c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2016-08-09T13:27:31Z (GMT). No. of bitstreams: 2 Dissertação - Tainá Carvalho Guerreiro - 2015.pdf: 1793254 bytes, checksum: b06a919b2f95dde4661fe77445d3668c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2015-07-08 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Streptococcus pneumoniae remains as a major cause of childhood morbidity and mortality worldwide, especially in developing countries. Nasopharyngeal colonization is the key of the development of pneumococcal diseases as well as for horizontal spread of this pathogen in the community. Children are the main reservoir of S. pneumoniae and act as vectors in the transmission chain of this microorganism. Pneumococcal conjugate vaccines protect against pneumococcal disease caused by vaccine serotypes, also contributes to the protection against colonization by the same serotypes. In 2010, PCV10 was introduced in the childhood immunization program of Brazil. This is a population-based study that was conducted immediately after the introduction of the vaccine in order to determine the carriage rate of this pathogen in children attending in day care centers in Goiania. These data may be used as a predictor for evaluating the dynamic of the circulating serotypes into the community after the vaccine introduction. Between October and November 2010, nasopharyngeal swabs were collected from 853 children ranging from 36 to 59 months attending in day care centers in Goiania. Isolation and identification of S. pneumoniae were done after the incubation step on broth-enriched for 6 h and posterior plating on blood agar. Isolates that were α-haemolytic, optochin-sensitive and soluble in bile were identified as S. pneumoniae. The isolates were serotyped by cmPCR. The database had been built with the statistical program SPSS (Chicago, IL, USA) version 18.0. The possible risk factors were assessed by multivariate Poisson regression. The level of probability of 0.05 (two-tailed) was used to determine statistical significance. The prevalence of pneumococcus carrier was 57.6% (CI95%: 54.2% - 60.9%). According to the multivariate Poisson regression analysis, children aged 36-47 months (IRR: 1.117; CI95%: 1.007-1.238; p: 0.035) and children in whose houses had four or more residents (IRR: 1.1214; CI95%: 1.078-1.368; p 0.001) were considered risk factors independently associated to pneumococcal colonization. The variable family income equal to or greater than three minimum wages was considered a protective factor independently associated to pneumococcal colonization (IRR: 0.787; CI95%: 0.627-0.990; p 0.041). The most prevalent serotypes and serogroups founded were 6A/6B/6C/6D (n=80; 16.3%), 14 (n=47; 9.6%), 23F (n=46; 9.4%), 19F (n=43; 8.8%), 15B/15C (n=30; 6.1%), 11A/11D (n=28; 5.7%), 3 (n=22; 4.5%) and 19A (n=16; 3.3%). Our results showed a high prevalence of pneumococcal colonization among the study population, indicating that colonization by this microrganism is common among children, especially in environments that favor crowding. The main serotypes/serogroups are cover by PCV10. / Streptococcus pneumoniae é o patógeno responsável pelas maiores taxas de morbidade e mortalidade em crianças, principalmente em países em desenvolvimento. A colonização da nasofaringe é a chave para o desenvolvimento das doenças pneumocócicas, bem como para a transmissão horizontal desse patógeno na comunidade. Crianças são o principal reservatório de S. pneumoniae e atuam como vetores dentro da cadeia de transmissão desse microrganismo. As vacinas pneumocócicas conjugadas (PCV) protegem contra as doenças pneumocócicas causadas pelos sorotipos vacinais, atuando também na proteção contra a colonização pelos mesmos sorotipos. Em 2010, o Brasil introduziu a PCV10 no programa de imunização infantil. Este trabalho é um estudo de base populacional que foi conduzido imediatamente após a introdução da PCV10 para determinar a taxa de portador desse patógeno em crianças não vacinadas que frequentam creches no município de Goiânia. Esses dados poderão ser utilizados como linha de base epidemiológica para avaliação da dinâmica dos sorotipos circulantes na comunidade após a introdução da vacina. Foram coletados, nos meses de outubro e novembro de 2010, 853 swabs de secreção da nasofaringe em crianças entre 36 a 59 meses que frequentavam creches no município de Goiânia. Para o isolamento e identificação de S. pneumoniae as amostras foram incubadas por 6 h em caldo enriquecido e semeadas em ágar sangue. Colônias α-hemolíticas sensíveis à optoquina e à bile foram identificadas como S. pneumoniae. Os isolados foram sorotipados por PCR multiplex convencional. A base de dados foi construída com o programa estatístico SPSS (Chicago, IL, USA) versão 18.0. Os possíveis fatores de risco foram avaliados por regressão de Poisson multivariada. O nível de probabilidade de 0,05 (bi-caudal) foi utilizado para determinar a significância estatística. A prevalência de portador do pneumococo foi de 57,6% (IC95%: 54,2% - 60,9%). De acordo com a análise multivariada crianças com idade entre 36-47 meses de idade (IRR: 1,117; IC95%:1,007 – 1,238; p= 0,035) e crianças em cujos domicílios haviam quatro ou mais pessoas residentes (IRR: 1,1214; IC95%: 1,078 – 1,368; p= 0,001) foram considerados fatores de risco independentemente associados para a colonização pneumocócica. A variável renda familiar igual ou superior a três salários mínimos foi considerada um fator protetor independentemente associado para a colonização pneumocócica (IRR: 0,787; IC95%: 0,627 – 0,990; p= 0,041). Os sorotipos/sorogrupos mais prevalentes foram 6A/6B/6C/6D (n=80; 16,3%), 14 (n=47; 9,6%), 23F (n=46; 9,4%), 19F (n=43; 8,8%), 15B/15C (n=30; 6,1%), 11A/11D (n=28; 5,7%), 3 (n=22; 4,5%) e 19A (n=16; 3,3%). Nossos resultados mostraram uma alta prevalência de colonização por pneumococo entre a população estudada, indicando que a colonização por esse microrganismo é comum entre crianças, principalmente em ambientes que favorecem a aglomeração. Os principais sorotipos/sorogrupos encontrados são contemplados pela PCV10.